mirna

BNET Resources

• sort by:
• Relevance
• Date
• Popularity

Glaxo-Regulus Kicks Off an mirna Land Grab

GlaxoSmithKline's willingness to bet up to $600 million on a tiny biotech called Regulus Therapeutics kicks off the latest pharma land grab -- this one for treatments that rely on tiny molecules called microRNAs, or miRNAs for short. New drug technologies -- or "modalities," as the industry...

Tags: Pharmaceutical Company, miRNA, Regulus Therapeutics, Glaxo, Biotechnology, David P. Hamilton

Blog posts 2008-04-18

Additional Resources

Invitrogen Scientists Link microRNA Sequences to Cancer Using RNA Samples from BioServe

CARLSBAD, Calif. & BELTSVILLE, Md. -- In research demonstrating that RNA previously thought to have no biological relevance may be of use for therapeutic and diagnostic targets, Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, and BioServe, the leading provider of clinically annotated...

Articles 2008-05-07

Regulus Therapeutics Exclusively Licenses Intellectual Property from Stanford University Relating to microRNA Antagonists to Treat Inflammatory Diseases

CAMBRIDGE, Mass. & CARLSBAD, Calif. -- Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA miRNA therapeutics, announced today that it has obtained exclusive rights from Stanford University to worldwide patent applications covering methods...

Articles 2008-05-06

Asuragen Launches The First Validated microRNA Diagnostic Assay

AUSTIN, Texas -- Asuragen, Inc. announced today the launch of the first microRNA miRNA test for clinical diagnosis and disease management. The assay utilizes qRT-PCR technology* and differentiates between chronic pancreatitis and pancreatic cancer pancreatic ductal adenocarcinoma. Pancreatic cancer is the 4th leading cause of cancer related deaths in the...

Articles 2008-04-23

febit First to Offer miRBase 11.0 Biochip

MEDFORD, Mass. and HEIDELBERG, Germany, April 14 /PRNewswire/ -- febit today announced its newest miRNA Biochip based on the new miRBASE version 11.0 which has been released by the Wellcome Trust Sanger Institute yesterday. The new GeniomR Biochip opens up the most up-to-date scientific information for miRNA microarray experiments....

Articles 2008-04-14

Targeted Genetics Announces Publication of Preclinical Data Supporting the Use of AAV Vectors to Deliver siRNA

Targeted Genetics Corporation (NASDAQ: TGEN)today announced the publication of preclinical data characterizing thenovel use of Adeno-Associated Viral AAV vectors to deliver smallinterfering RNA siRNA for the treatment of Huntington's disease. The goalof this research is to assess the use of interfering RNA to silence themutant huntingtin gene and thus, reduce...

Articles 2008-04-09

Agilent Technologies Expands mirna Microarray Catalog with New Human, Mouse and Rat Assays

SANTA CLARA, Calif. -- Agilent Technologies Inc. (NYSE:A) today introduced three new microRNA microarray designs: Human miRNA Microarray v2.0, Mouse miRNA Microarray v1.0 and Rat miRNA Microarray v1.0. All are based on the Sanger Institute's miRBase 10.1, updated in December 2007. "Researchers tell us that they value specificity...

Articles 2008-04-09

New MicroRNA Analysis Tools From Applied Biosystems Advance Cancer Research

TaqMan[R] Reagents Speed Workflows and Enable Analysis of Trace Amounts of RNA in Cell and Tumor Samples FOSTER CITY, Calif. -- Research related to a class of non-coding small RNA molecules called microRNAs miRNAs is one of the fastest-growing areas in biomedical research. These molecules have been found...

Articles 2008-04-09

Asuragen Launches mirna Therapeutics

Asuragen launches Mirna Therapeutics to Develop and Commercialize microRNA Oncology Therapeutics Mirna is Developing "miRNA Replacement" Therapies, Using miRNAs As Drugs to Correct the Down-Regulation Of miRNAs That Occurs in Many Human Cancers AUSTIN, Texas -- Asuragen, Inc. announced today the launch of Mirna Therapeutics, a...

Articles 2008-04-03

RxGen and Santaris Pharma Use LNA-antimiR Technology to antagonize the liver-expressed microRNA-122 in Non-Human Primates and to Safely Lower Serum Cholesterol

HAMDEN, Conn. & H0RSHOLM, Denmark -- In a study published in the journal Nature today, Santaris Pharma and RxGen Inc., a specialty pharma services company demonstrated that a systemically delivered Locked Nucleic Acid LNA compound could safely and effectively silence a microRNA target in African green monkeys. The study shows...

Articles 2008-03-27

Yale and Asuragen Scientists Show That a microRNA Can Reduce Lung Cancer Growth

NEW HAVEN, Conn. & AUSTIN, Texas -- A microRNA miRNA molecule known as let-7 substantially reduced cancer growth in multiple mouse models of lung cancer as reported by researchers at Yale University School of Medicine and Asuragen, Inc. in the journal Cell Cycle. Cancer afflicts 1.5 million people...

Articles 2008-03-25

Yale Scientists Show that a microRNA Can Reduce Lung Cancer Growth.

M2 PRESSWIRE-24 March 2008-Yale University: Yale Scientists Show that a microRNA Can Reduce Lung Cancer GrowthC1994-2008 M2 COMMUNICATIONS LTD RDATE:20032008 New Haven, Conn. -- A small RNA molecule, known as let-7 microRNA miRNA, substantially reduced cancer growth in multiple...

Articles 2008-03-24

The Global RNAi Market is Projected to Grow at 25.6% Compounded Annually From 2005 to 2012

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c85063) has announced the addition of RNAi 2008 to their offering. This Market Insight Report on RNAi covers both products and services in the RNAi industry. The global RNAi market is analyzed by Tools/Products and Applications for each of the geographic regions-United...

Articles 2008-03-07

The Global RNAi Market is Projected to Grow at 25.6% Compounded Annually from 2005 to 2012.

M2 PRESSWIRE-6 March 2008-Research and Markets: The Global RNAi Market is Projected to Grow at 25.6% Compounded Annually from 2005 to 2012C1994-2008 M2 COMMUNICATIONS LTD RDATE:07032008 Dublin - Research and Markets (http://www.researchandmarkets.com/reports/c85065) has announced the addition of RNAi...

Articles 2008-03-06

Detection and Characterization of Placental MicroRNAs in Maternal Plasma

BACKGROUND: The discovery of circulating fetal nucleic acids in maternal plasma has opened up new possibilities for noninvasive prenatal diagnosis. MicroRNAs miRNAs, a class of small RNAs, have been intensely investigated recently because of their important regulatory role in gene expression. Because nucleic acids of placental origin are released into...

Articles 2008-03-01

Invitrogen Teams with Genisphere to Advance Epigenetic Research

Companies Offer New MicroRNA Labeling and Detection Kits CARLSBAD, Calif. & HATFIELD, Pa. -- Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, will become the exclusive provider of fluorescent microRNA microarray labeling kits using Genisphere Inc.'s 3DNA[R] dendrimer signal amplification technology,...

Articles 2008-02-27

Local births

Birth & Family Place - HART, Katie and Ezekiel, Bountiful, boy, Jan. 20 RIDDLE, AManda and Stuart, Kaysville, girl, Jan. 17 Jordan Valley Hospital - ALVAREZ, Mirna Denise and GUERRERO, Victor Jr., West Valley City, girl, Jan. 22...

Articles 2008-02-11

Development of a Dual-Luciferase Reporter System for In Vivo Visualization of MicroRNA Biogenesis and Posttranscriptional Regulation

MicroRNAs miRNAs function in mammalian cells via translational repression or messenger RNA mRNA cleavage of target genes by base-pairing with 3' untranslated regions UTRs of target mRNAs. Although miRNAs are involved in cell differentiation or organ development, posttranscritptional regulation of miRNA is not well understood. Here, we developed a dual-luciferase...

Articles 2008-02-01

Danish biotech company Exiqon A/S acquires US company Oncotech Inc

NORDIC BUSINESS REPORT-21 January 2008-Danish biotech company Exiqon A/S acquires US company Oncotech IncC1994-2008 M2 COMMUNICATIONS LTD http://www.m2.com Danish biotech company Exiqon A/S said on Monday (21 January) that it has signed a firm agreement to acquire the US company Oncotech Inc. The agreement is based...

Articles 2008-01-21

Helicos BioSciences Announces MicroRNA Collaboration with mirna Expert

Partnership with Dr. Victor Ambros to Expand Genomic Discoveries CAMBRIDGE, Mass. -- Helicos BioSciences (Nasdaq:HLCS), a life science company focused on innovative genetic analysis technologies, announced today a formal collaboration with Dr. Victor Ambros to apply the quantitative power of True Single Molecule Sequencing (tSMSTM) to develop a...

Articles 2008-01-09